Psychedelics biotech set to go public via SPAC — pushing IV form of psilocybin into PhI

Psychedelics biotech Eleusis has its eyes on an expansion, and it’s going the SPAC route to get it.

The biotech announced earlier today that it’s teaming up with a SPAC born out of asset manager Silver Spike Capital to make Eleusis a public company. Once the deal goes through sometime in Q2 or Q3 this year, the combined company will be operated through new holding company Eleusis Inc and trade on Nasdaq under the ticker $ELEU.